List view / Grid view
19 November 2013 | By Boehringer Ingelheim
Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention...
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
3 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
17 June 2013 | By Boehringer Ingelheim
New long-term data from the RELY-ABLE® study...
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
5 November 2012 | By Boehringer Ingelheim
"We welcome the positive conclusions reached..."
24 September 2012 | By Pfizer
For the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation...
29 August 2012 | By Boehringer Ingelheim
New one-year follow-up results from the global RE-LY AF registry...
27 August 2012 | By Boehringer Ingelheim
40,000 people estimated to be saved from a stroke related to non-valvular atrial fibrillation...
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
20 December 2011 | By Bayer HealthCare
The only new oral anticoagulant approved in three indications across all 27 EU member states...
